The fundamentals, she says, are the same for everyone on the medications or not: enough protein, enough fiber, and nutrient-dense foods that are not overly processed
Viking Therapeutics Sector: Dual and triple agonists for obesity, metabolic, and liver disease HQ: San Diego, CA Year Founded: 2012 Origin Story: The company built its pipeline around small molecule and peptide candidates licensed from academic and pharma sources, eventually advancing VK2735, a dual GLP-1/GIP receptor agonist designed to be the first such therapy available in both oral and injectable formulations
Foundayo was FDA approved on April 1, 2026 (1)
[57] demonstrated that GLP-1 based agents were associated with a three-fold increased risk of pancreatic enzyme elevation relative to controls, yet did not indicate a significant rise in pancreatitis or pancreatic cancer
Look here
Recognising these realities is essential before committing to GLP-1-based treatment